As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones ...

Bio-Techne develops specialized reagents and diagnostic solutions for global research and clinical markets in the life sciences sector.

Minneapolis, Minnesota-based Bio-Techne Corporation (TECH) develops, manufactures, and sells life science reagents, ...

TECH expands via acquisitions and global growth, but biotech funding softness, U.S. academic spending pressure and ...

Bio-Techne (TECH) is back in focus after institutional investors such as Jefferies Financial Group and Madison Investments ...

Bio-Techne TECH reported fourth-quarter fiscal 2025 adjusted earnings per share (EPS) of 53 cents, which surpassed the Zacks Consensus Estimate by 6%. The bottom line improved from the year-ago figure ...

Combines chemiluminescence detection with dual-channel fluorescence in the near-infrared and infrared (NIR and IR) ranges for expanded multiplexing Enables up to 24 targets per sample and supports ...

Bio-Techne Corp. closed 27.94% short of its 52-week high of $72.16, which the company achieved on January 22nd.

Dr. Matt McManus to transition from his role as President, Diagnostics and Spatial Biology Segment, effective March 1, 2026 Steve Crouse, Senior Vice President of Bio-Techne's Analytical Solutions ...